Clinical Applications of Metronomic Chemotherapy

Metronomic chemotherapy is now, finally, in clinical use. After 20 years of preclinical development and clinical trials, the emerging data will be of paramount importance in allowing us to assess the impact of metronomic chemotherapy on different tumor types. Indeed, it is likely that the next decad...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Μορφή: Online
Γλώσσα:Αγγλικά
Έκδοση: MDPI - Multidisciplinary Digital Publishing Institute 2024
Θέματα:
Διαθέσιμο Online:ONIX_20240108_9783036592800_75
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
_version_ 1869524281715589120
collection Directory of Open Access Books
description Metronomic chemotherapy is now, finally, in clinical use. After 20 years of preclinical development and clinical trials, the emerging data will be of paramount importance in allowing us to assess the impact of metronomic chemotherapy on different tumor types. Indeed, it is likely that the next decade will see a major reassessment of the possible applications of metronomic chemotherapy, both alone and in combination with new therapeutic approaches such as immunotherapies, for the management of cancer. Moreover, the results of clinical trials will likely profoundly affect the direction of the laboratory efforts that are going on in parallel and aiming to improve the personalization of this therapeutic strategy. This Special Issue is our attempt to cover the past and present clinical results that have brought us to this pivotal moment and will form the basis of future clinical developments. Scientists and clinicians caring for cancer patients are well aware of the challenges in dealing with this particular therapeutic approach; one such challenge is obtaining improvements in patient survival without significant toxicity. This edition includes clinical research on chemotherapy and ongoing controversies related to metronomic chemotherapy.
format Online
id doab-20.500.12854ir-132416
institution Directory of Open Access Books
language eng
publishDate 2024
publishDateRange 2024
publishDateSort 2024
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-1324162024-03-31T13:10:42Z Clinical Applications of Metronomic Chemotherapy Bocci, Guido Francia, Giulio metronomic oral cancer oral squamous cell carcinoma metronomic chemotherapy metastatic castration-resistant prostate cancer cyclophosphamide side effects pediatric tumors etoposide valproic acid prostate cancer CRPC castration capecitabine paclitaxel immunomodulation angiogenesis microbiome breast cancer safety preclinical studies clinical studies pharmacokinetic studies biomarkers chemo-free DLBCL diffuse-large-b-cell-lymphoma elderly frail comprehensive geriatric assessment chemo-endocrine therapy FulVEC pediatric oncology brain tumors pharmacology medulloblastoma ATRT immunotherapy lymphoma vinorelbine checkpoint inhibitors thema EDItEUR::M Medicine and Nursing Metronomic chemotherapy is now, finally, in clinical use. After 20 years of preclinical development and clinical trials, the emerging data will be of paramount importance in allowing us to assess the impact of metronomic chemotherapy on different tumor types. Indeed, it is likely that the next decade will see a major reassessment of the possible applications of metronomic chemotherapy, both alone and in combination with new therapeutic approaches such as immunotherapies, for the management of cancer. Moreover, the results of clinical trials will likely profoundly affect the direction of the laboratory efforts that are going on in parallel and aiming to improve the personalization of this therapeutic strategy. This Special Issue is our attempt to cover the past and present clinical results that have brought us to this pivotal moment and will form the basis of future clinical developments. Scientists and clinicians caring for cancer patients are well aware of the challenges in dealing with this particular therapeutic approach; one such challenge is obtaining improvements in patient survival without significant toxicity. This edition includes clinical research on chemotherapy and ongoing controversies related to metronomic chemotherapy. 2024-01-08T14:48:58Z 2024-01-08T14:48:58Z 2023 book ONIX_20240108_9783036592800_75 9783036592800 9783036592817 https://directory.doabooks.org/handle/20.500.12854/132416 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/8451 https://mdpi.com/books/pdfview/book/8451 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-9281-7 10.3390/books978-3-0365-9281-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036592800 9783036592817 176 Basel open access
spellingShingle metronomic
oral cancer
oral squamous cell carcinoma
metronomic chemotherapy
metastatic castration-resistant prostate cancer
cyclophosphamide
side effects
pediatric tumors
etoposide
valproic acid
prostate cancer
CRPC
castration
capecitabine
paclitaxel
immunomodulation
angiogenesis
microbiome
breast cancer
safety
preclinical studies
clinical studies
pharmacokinetic studies
biomarkers
chemo-free
DLBCL
diffuse-large-b-cell-lymphoma
elderly
frail
comprehensive geriatric assessment
chemo-endocrine therapy
FulVEC
pediatric oncology
brain tumors
pharmacology
medulloblastoma
ATRT
immunotherapy
lymphoma
vinorelbine
checkpoint inhibitors
thema EDItEUR::M Medicine and Nursing
Clinical Applications of Metronomic Chemotherapy
title Clinical Applications of Metronomic Chemotherapy
title_full Clinical Applications of Metronomic Chemotherapy
title_fullStr Clinical Applications of Metronomic Chemotherapy
title_full_unstemmed Clinical Applications of Metronomic Chemotherapy
title_short Clinical Applications of Metronomic Chemotherapy
title_sort clinical applications of metronomic chemotherapy
topic metronomic
oral cancer
oral squamous cell carcinoma
metronomic chemotherapy
metastatic castration-resistant prostate cancer
cyclophosphamide
side effects
pediatric tumors
etoposide
valproic acid
prostate cancer
CRPC
castration
capecitabine
paclitaxel
immunomodulation
angiogenesis
microbiome
breast cancer
safety
preclinical studies
clinical studies
pharmacokinetic studies
biomarkers
chemo-free
DLBCL
diffuse-large-b-cell-lymphoma
elderly
frail
comprehensive geriatric assessment
chemo-endocrine therapy
FulVEC
pediatric oncology
brain tumors
pharmacology
medulloblastoma
ATRT
immunotherapy
lymphoma
vinorelbine
checkpoint inhibitors
thema EDItEUR::M Medicine and Nursing
topic_facet metronomic
oral cancer
oral squamous cell carcinoma
metronomic chemotherapy
metastatic castration-resistant prostate cancer
cyclophosphamide
side effects
pediatric tumors
etoposide
valproic acid
prostate cancer
CRPC
castration
capecitabine
paclitaxel
immunomodulation
angiogenesis
microbiome
breast cancer
safety
preclinical studies
clinical studies
pharmacokinetic studies
biomarkers
chemo-free
DLBCL
diffuse-large-b-cell-lymphoma
elderly
frail
comprehensive geriatric assessment
chemo-endocrine therapy
FulVEC
pediatric oncology
brain tumors
pharmacology
medulloblastoma
ATRT
immunotherapy
lymphoma
vinorelbine
checkpoint inhibitors
thema EDItEUR::M Medicine and Nursing
url ONIX_20240108_9783036592800_75